Brief: Data For GlycoMimetics’ Lead Investigational Drug Uproleselan Published
23/09/2021 21:03
Sept 23 (Reuters) - GlycoMimetics Inc GLYC.O :
* EFFICACY AND SAFETY DATA FOR GLYCOMIMETICS’ LEAD
INVESTIGATIONAL
DRUG UPROLESELAN PUBLISHED IN BLOOD
* GLYCOMIMETICS INC - MANUSCRIPT HIGHLIGHTS MRD NEGATIVE
RATE OF
69% IN RELAPSED/REFRACTORY PATIENT POPULATION
Source text for Eikon: ID:nBwbs0Cyja
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering